

## News Release

For iCAD:  
Kevin McGrath  
Cameron Associates  
212-245-4577  
[Kevin@cameronassoc.com](mailto:Kevin@cameronassoc.com)  
[www.icadmed.com](http://www.icadmed.com)

For Viatronix:  
Cathy Callegari  
212-579-1370  
[callpr@aol.com](mailto:callpr@aol.com)  
[www.viatronix.com](http://www.viatronix.com)

### **iCAD and Viatronix Announce Licensing Agreement for Computed Tomography (CT) Lung CAD**

#### **Viatronix Will Integrate iCAD's Second Look® Lung CAD Software with its 3D Visualization Products**

**Nashua, NH and Stony Brook, NY (November 29, 2004)** – iCAD, Inc. (Nasdaq: ICAD), which designs, develops and markets Computer Aided Detection (CAD) imaging technology and systems for the early detection of breast cancer and other medical applications, and Viatronix, Inc. a global leader in innovative 3-D computer diagnostic medical imaging and treatment technologies, today announced a development and distribution agreement to provide iCAD's proprietary CAD technology for use with Viatronix's 3-D CT visualization software. Computer-aided detection is a software technology designed to identify suspicious areas during CT screening exams, and the planned new CAD capability is intended to assist physicians in finding cancerous and pre-cancerous lung nodules more quickly and precisely. Under this agreement, Viatronix will distribute the new CAD option after development by iCAD is completed and after the product has been approved by the Food and Drug Administration.

“Building on iCAD's demonstrated effectiveness in early detection of cancer,” said Zaffar Hayat, Viatronix's President and CEO. “We believe we can provide an important tool that would greatly enhance the diagnostic capability of the radiologists in highlighting and recognizing key indicators of Lung cancer,”

“Viatronix is a leading innovator and developer of diagnostic 3D imaging software, which enables physicians to interactively view patients' vital organs and anatomical structures,” said W. Scott Parr, President and Chief Executive Officer of iCAD, Inc. “It is a privilege to work with Viatronix in further developing and promoting iCAD software technology for early detection of lung cancer.”

#### **About iCAD, Inc.**

iCAD engineers, develops, manufactures and markets computer aided detection (CAD) products for the early detection of breast cancer and other health-care related applications. iCAD is the only independent, integrated digitizer hardware and CAD software company offering computer aided detection solutions. Already a market leader in delivery of software-based solutions for early detection of breast cancer, iCAD has announced that is currently involved in research and development applying its pattern recognition technologies to earlier detection of lung and colon cancers. More information on iCAD's products can be found at [www.icadmed.com](http://www.icadmed.com)

**About Viatronix, Inc.**

Viatronix is a leading innovator and developer of diagnostic 3D imaging software, which enables physicians to interactively view patients' vital organs and anatomical structures. The Viatronix PACS-integratable V3D-Explorer has patent protected technology that enables 3D visualization of organs from patient data acquired by standard imaging equipment via minimally invasive or non-invasive methods. The Viatronix V3D-Colon allows physicians to interactively view the colon reconstructed from a CT scan, providing visualization of the inner surface of the colon, including polyps. The Viatronix V3D-Calcium Scoring aids physicians in determining the amount of calcium plaque accumulation in the coronary arteries. V3D-Vascular is the latest addition to the V3D System. In seconds, this breakthrough software permits rapid segmentation and visualization of complex arterial structures using 3D volume rendering, maximum intensity projection and simulated x-ray views. Viatronix, through application of its V3D technology, is developing additional innovative products that will be useful for earlier detection of diseases, treatment planning, and follow-up evaluation. For further information, call toll free (866) 887-4636 or log on to [www.viatronix.com](http://www.viatronix.com)

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, successful completion of research and development objectives, achievement of necessary regulatory approvals, the risks or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s other filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The company is under no obligation to provide any updates to any information contained in this release.

Second Look is a registered trademark of iCAD, Inc. All rights reserved.